ericsphotography/E+ via Getty Images A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb ( NYSE: BMY ) that alleged the drugmaker wronged holders of Celgene contingency value rights by delaying regulatory approvals for three Celgene drugs. A U.
S. district court judge.
